(Q33349630)

English

Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

pharmacokinetics

1 reference

based on heuristic

inferred from title

8

object named as

J H Beijnen

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

C Twelves

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

K Hoekman

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A Bowman

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

J B Vermorken

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A Anthoney

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

J Smyth

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

C van Kesteren

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

J Uiters

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

J Wanders

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

J Gomez

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

C Guzmán

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

J Jimeno

13

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A Hanauske

14

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

1 September 2003

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

European Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

39

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1842-1851

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900458-1

7 January 2021

based on heuristic

inferred from DOI database lookup

High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900458-1

7 January 2021

based on heuristic

inferred from DOI database lookup

DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900458-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: results of a phase III trial. Swiss Group for Clinical Cancer Research (SAKK)

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900458-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900458-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900458-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900458-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900458-1

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro schedule-dependency of myelotoxicity and cytotoxicity of Ecteinascidin 743 (ET-743).

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900458-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900458-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900458-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of Ecteinascidin 743, a new potent marine-derived anticancer drug, in human plasma by high-performance liquid chromatography in combination with solid-phase extraction

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900458-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Quantitative determination of Ecteinascidin 743 in human plasma by miniaturized high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900458-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900458-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0959-8049(03)00458-1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33349630&oldid=2143285117"